Jiangsu Kangrun Biotechnology

Jiangsu Kangrun Biotechnology is a high-tech enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and automated instruments. The company's core technology centers on its proprietary magnetic bead chemiluminescence immunoassay (CLIA) platform, which supports a broad menu of tests for infectious diseases, tumor markers, cardiac markers, and hormones. Beyond diagnostics, Kangrun leverages its expertise in recombinant protein expression and antibody engineering to develop high-quality biological raw materials and explore recombinant vaccine candidates, including a program for COVID-19. Based in Changzhou, China, the company operates GMP-compliant facilities and serves a global market of hospitals and clinical laboratories. Kangrun has received significant backing from prominent Chinese venture capital firms to expand its diagnostic portfolio and R&D capabilities.